RVMD,TNGX Stock Price and Quote

Peers: AMGN GILD VRTX BMY MRNA PFE REGN ILMN BIIB EXEL

| Held by: VTI VB VBK VXF XBI IBB SCHA IWR SCHM IWD

Index	-	P/E	-	EPS (ttm)	-5.18	Insider Own	14.49%	Shs Outstand	189.71M	Perf Week	-1.21%
Market Cap	18.62B	Forward P/E	-	EPS next Y	-6.60	Insider Trans	-1.66%	Shs Float	165.30M	Perf Month	-20.55%
Enterprise Value	16.85B	PEG	-	EPS next Q	-1.58	Inst Own	91.44%	Short Float	7.91%	Perf Quarter	46.30%
Income	-960.98M	P/S	-	EPS this Y	-57.14%	Inst Trans	2.99%	Short Ratio	3.88	Perf Half Y	167.38%
Sales	0.00M	P/B	11.44	EPS next Y	-17.38%	ROA	-47.87%	Short Interest	13.07M	Perf YTD	20.92%
Book/sh	8.42	P/C	9.64	EPS next 5Y	-16.80%	ROE	-60.76%	52W High	124.49 -22.64%	Perf Year	133.08%
Cash/sh	9.99	P/FCF	-	EPS past 3/5Y	-11.66% -27.80%	ROIC	-55.26%	52W Low	29.17 230.17%	Perf 3Y	277.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.87% 3.53%	Perf 5Y	93.47%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-44.24%	Oper. Margin	-	ATR (14)	4.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.05	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	46.32	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.05	EPS Q/Q	-72.19%	SMA20	-5.96%	Beta	1.00	Target Price	121.94
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	3.00%	Rel Volume	0.47	Prev Close	97.33
Employees	534	LT Debt/Eq	0.09	Earnings	Nov 05 AMC	SMA200	68.02%	Avg Volume	3.37M	Price	96.31
IPO	Feb 13, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.29% -100.00%	Trades		Volume	1,569,801	Change	-1.05%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Initiated	Wolfe Research	Outperform	$75
Nov-03-25	Initiated	RBC Capital Mkts	Outperform	$77
Oct-21-25	Initiated	Mizuho	Outperform	$90
Oct-16-25	Resumed	Stifel	Buy	$85
Sep-12-25	Resumed	Raymond James	Strong Buy	$72
Sep-05-25	Initiated	Truist	Buy	$99
Aug-19-25	Initiated	Piper Sandler	Overweight	$75
Aug-15-25	Initiated	Wells Fargo	Overweight	$67
Jul-15-25	Initiated	Goldman	Buy	$65
Jul-16-24	Reiterated	Needham	Buy	$46 → $62
Jul-12-24	Initiated	Barclays	Overweight	$52
Jul-08-24	Initiated	Jefferies	Buy	$63
Apr-12-24	Reiterated	Needham	Buy	$36 → $46
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy	$36 → $48
Mar-11-24	Initiated	Piper Sandler	Overweight	$43
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy	$31 → $34
Jan-04-24	Initiated	Wedbush	Outperform	$41
Nov-16-23	Initiated	Raymond James	Outperform	$30
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight	$32 → $38
Dec-14-22	Initiated	Needham	Buy	$31

Show Previous Ratings

Feb-13-26 02:07PM	Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat (MarketBeat)
Feb-04-26 04:05PM	Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-29-26 08:00AM	Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor (GlobeNewswire)
Jan-27-26 10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
06:23AM	Stock Index Futures Gain on Tech Boost, FOMC Meeting and Earnings in Focus (Barchart)
05:02AM	Loading…
05:02AM	Revolution Medicines (RVMD) Dives 16.9% as Merck Withdraws Takeover Plan (Insider Monkey)
03:39AM	Stock Market Today: Nasdaq Futures Rise Ahead of Earnings; Yen Weakens (The Wall Street Journal)
Jan-26-26 07:36PM	Why Revolution Medicines Stock Plummeted by Almost 17% Today (Motley Fool) -16.87%
04:56PM	Stocks to Watch Monday Recap: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
04:32PM	Stocks Close Higher Ahead of Heavy Earnings Week and FOMC Meeting (Barchart)
01:48PM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
01:12PM	Stock Market Today: Trump's Medicare announcement slams health insurers (TheStreet)
12:47PM	Merck Ends Acquisition Talks With Revolution Medicines After Valuation Dispute (GuruFocus.com)
11:41AM	Stocks See Support Ahead of Heavy Earnings Week and FOMC Meeting (Barchart)
09:44AM	Loading…
09:44AM	Stocks to Watch Monday: CoreWeave, American Airlines, IonQ, Enphase (The Wall Street Journal)
09:09AM	Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit (Investing.com)
07:52AM	Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? (Benzinga)
07:19AM	MSD ends takeover talks with Revolution Medicines (Pharmaceutical Technology)
06:22AM	Stocks Set for Muted Open After Trumps Tariff Threats, Big Tech Earnings and Fed Meeting in Focus (Barchart)
06:01AM	Revolution Medicines Stock Sinks After Merck Deal Talks Collapse (Benzinga)
Jan-25-26 02:43PM	Merck No Longer In Talks With Revolution Medicines: WSJ (Barrons.com)
02:30PM	Merck No Longer in Talks to Buy Revolution Medicines (The Wall Street Journal)
Jan-22-26 02:31PM	Biotech stocks are among today's winners (MarketWatch)
09:10AM	Jim Cramer Highlights "Takeover Interest" in Revolution Medicines (Insider Monkey)
Jan-16-26 01:43AM	On biotechs biggest stage, renewed excitement gets a stress test (BioPharma Dive)
Jan-13-26 05:59AM	JPM26: Day 1 drug prices and policy changes drive the agenda (Pharmaceutical Technology)
Jan-12-26 08:51AM	AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense (Zacks)
07:54AM	JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree (Pharmaceutical Technology)
Jan-11-26 08:01AM	Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio? (Benzinga)
08:16PM	Loading…
Jan-09-26 08:16PM	Why Revolution Medicines Stock Surged by 11% Today (Motley Fool) +10.48%
04:46PM	Deal Dispatch: Saks Faces A Luxury Liquidity Crisis, Soho House Gets Quiet (Benzinga)
04:43PM	These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More (Barrons.com)
04:38PM	S&P 500 Rallies to a New Record High on US Economic Optimism (Barchart)
03:18PM	These Stocks Are Moving the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More (Barrons.com)
02:58PM	Merck in Talks to Buy Revolution Medicines for Around $30 Billion (The Wall Street Journal)
12:03PM	Merck in Talks to Buy Revolution Medicines Per Financial Times Report (Zacks)
11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
09:54AM	Revolution Medicines Stock Jumps. Takeover Buzz Grows, Another Suitor Emerges. (Barrons.com)
06:20AM	December Jobs Report Miss Forecasts While Unemployment Defies Expectations (Barchart)
05:56AM	These Stocks Are Moving the Most Today: Opendoor, Rocket Cos., GM, Apple, Glencore, Revolution Medicines, Tilray, and More (Barrons.com)
05:54AM	Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges. (Barrons.com)
01:52AM	Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal - Stock Soars Overnight (Benzinga)
Jan-08-26 07:51PM	Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn (Financial Times)
04:25PM	Revolution Medicines stock rises on Merck acquisition talks (Investing.com)
03:58PM	Merck in talks to buy biotech Revolution Medicines, FT reports (Reuters)
01:41PM	AbbVie Stock Drops After Guidance Update, Wolfe Downgrade And Deal Denial (Benzinga)
01:21PM	What's Going With Cancer Biotech Erasca Stock On Thursday? (Benzinga)
11:23AM	Stock Indexes Mixed on Big Tech Weakness and Higher Bond Yields (Barchart)
09:11AM	RVMD Stock Hits a Record High on Rumored Takeover Interest (Zacks)
08:38AM	These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Revolution Medicines, AbbVie, Costco, and More (Barrons.com)
08:00AM	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib (GlobeNewswire)
07:38AM	AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. (Barrons.com)
03:13AM	Why Revolution Medicines Shares Are Sliding After Hours On Wednesday (Benzinga)
Jan-07-26 09:18PM	Revolution Medicines (RVMD) Hits All-Time High on Buyout Buzz; Buyer Denies Talks (Insider Monkey) +28.63%
05:44PM	Revolution Medicines Draws Takeover Interest (The Wall Street Journal)
03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com)
02:48PM	AbbVie Near Deal for Revolution Medicines (The Wall Street Journal)
Jan-05-26 04:05PM	Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-25 08:00AM	Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy (GlobeNewswire)
Dec-05-25 11:30AM	Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 11:00AM	This Oncology Stock Just Hit New All-Time Highs (Barchart)
Nov-06-25 01:59PM	Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
12:05AM	Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 04:02PM	Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
Nov-04-25 04:05PM	Revolution Medicines to Participate in November 2025 Investor Conferences (GlobeNewswire)
07:24AM	Revolution Medicines Inc (RVMD) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-03-25 09:42AM	Boeing upgraded, Charter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 04:05PM	Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 (GlobeNewswire)
Oct-27-25 08:00AM	Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer (GlobeNewswire) +6.44%
Oct-22-25 12:12PM	Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor (GlobeNewswire)
Oct-20-25 08:25AM	FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks (GuruFocus.com)
Oct-19-25 03:21AM	Jim Cramer Says Revolution Medicines "Is a Speculative Situation" (Insider Monkey)
Oct-17-25 10:17AM	The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. (Investor's Business Daily) +8.90%
Oct-16-25 08:00PM	Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program (GlobeNewswire)
Oct-02-25 09:45AM	Revolution Medicines, Inc. (RVMD) Insider Sells Shares (Insider Monkey)
Sep-29-25 09:00AM	Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer (GlobeNewswire)
Sep-25-25 06:15AM	These 2 Stocks Could Be Prime Takeover Targets, According to Analysts (TipRanks)
Sep-12-25 09:00AM	Morning Movers: Kroger rises following second quarter results (TipRanks)
Sep-11-25 07:42AM	Revolutions daraxonrasib moves to Phase III after PDAC hat-trick (Clinical Trials Arena) +14.31%
Sep-10-25 04:02PM	Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Sep-02-25 01:34AM	Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress (Insider Monkey)
Aug-28-25 11:49PM	Here's What the Wall Street Thinks About Revolution Medicines (RVMD) (Insider Monkey)
Aug-22-25 11:57PM	Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating (Insider Monkey)
Aug-15-25 09:32AM	Target downgraded, Salesforce upgraded: Wall Street's top analyst calls (The Fly)
Aug-13-25 03:11PM	Revolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer (Insider Monkey)
Aug-06-25 04:02PM	Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress (GlobeNewswire)
07:00AM	Royalty Pharma Reports Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 09:28AM	What To Expect From Revolution Medicines Inc (RVMD) Q2 2025 Earnings (GuruFocus.com)
Jul-30-25 04:05PM	Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 (GlobeNewswire)
Jul-28-25 09:55AM	Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade (Zacks)
Jul-24-25 04:00PM	Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor (GlobeNewswire)
04:00AM	iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments (PR Newswire)
Jul-23-25 08:00AM	Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib (GlobeNewswire)
Jul-16-25 09:39AM	Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs (Insider Monkey)
Jul-09-25 08:00AM	Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates (GlobeNewswire) +5.71%
12:55AM	Revolution Medicines' Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations (Insider Monkey)
Jul-06-25 04:00AM	Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors (Insider Monkey)
Jul-02-25 03:20AM	Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress (Insider Monkey)
Jun-30-25 08:00AM	Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors (Business Wire)

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GOLDSMITH MARK A	See Remarks	Feb 06 '26	Option Exercise	0.54	24,010	12,965	256,479	Feb 10 05:30 PM
Cislini Jeff	General Counsel	Jan 21 '26	Sale	115.60	908	104,965	46,976	Jan 23 04:31 PM
JEFFREY TODD CISLINI	Officer	Jan 21 '26	Proposed Sale	116.22	908	105,528		Jan 21 04:23 PM
Horn Margaret A	Chief Operating Officer	Jan 07 '26	Option Exercise	38.47	75,000	2,885,286	216,053	Jan 09 04:20 PM
Horn Margaret A	Chief Operating Officer	Jan 07 '26	Sale	100.56	75,000	7,542,023	141,053	Jan 09 04:20 PM
Anders Jack	Chief Financial Officer	Jan 07 '26	Option Exercise	42.45	10,000	424,500	118,065	Jan 09 04:20 PM
Anders Jack	Chief Financial Officer	Jan 07 '26	Sale	98.00	10,000	980,000	108,065	Jan 09 04:20 PM
MARGARET A HORN	Officer	Jan 07 '26	Proposed Sale	79.85	75,000	5,988,750		Jan 07 04:23 PM
JACK LEE ANDERS	Officer	Jan 07 '26	Proposed Sale	79.85	10,000	798,500		Jan 07 04:22 PM
Cislini Jeff	General Counsel	Dec 16 '25	Sale	76.82	2,688	206,484	47,884	Dec 18 04:17 PM
GOLDSMITH MARK A	See Remarks	Dec 16 '25	Sale	76.82	15,394	1,182,526	232,469	Dec 18 04:17 PM
Kelsey Stephen Michael	See Remarks	Dec 16 '25	Sale	76.82	5,447	418,423	278,600	Dec 18 04:16 PM
Horn Margaret A	Chief Operating Officer	Dec 16 '25	Sale	76.82	4,847	372,333	141,053	Dec 18 04:16 PM
Anders Jack	Chief Financial Officer	Dec 16 '25	Sale	77.09	3,104	239,289	108,065	Dec 18 04:15 PM
GOLDSMITH MARK A	Officer	Dec 15 '25	Proposed Sale	77.81	14,964	1,164,349		Dec 12 09:03 PM
Kelsey Stephen Michael	Officer	Dec 15 '25	Proposed Sale	77.81	5,296	412,082		Dec 12 09:00 PM
Cislini Jeff	Officer	Dec 15 '25	Proposed Sale	77.81	2,614	203,395		Dec 12 08:59 PM
Anders Jack	Officer	Dec 15 '25	Proposed Sale	77.81	3,017	234,753		Dec 12 08:57 PM
Horn Margaret A	Officer	Dec 15 '25	Proposed Sale	77.81	4,711	366,563		Dec 12 08:55 PM
Anders Jack	Chief Financial Officer	Nov 25 '25	Option Exercise	17.00	5,418	92,106	116,412	Nov 26 04:16 PM
Anders Jack	Chief Financial Officer	Nov 25 '25	Sale	74.00	5,418	400,932	110,994	Nov 26 04:16 PM
GOLDSMITH MARK A	See Remarks	Nov 25 '25	Option Exercise	4.09	60,000	245,400	307,863	Nov 26 04:15 PM
GOLDSMITH MARK A	See Remarks	Nov 25 '25	Sale	75.08	60,000	4,504,962	247,863	Nov 26 04:15 PM
GOLDSMITH MARK A	See Remarks	Nov 25 '25	Sale	75.00	6,000	450,000	67,424	Nov 26 04:15 PM
J H GOLDSMITH & M A GOLDSMITHC	Director	Nov 25 '25	Proposed Sale	73.66	3,000	220,980		Nov 25 04:29 PM
THE REBECCA GOLDSMITH REVOCABL	Director	Nov 25 '25	Proposed Sale	73.66	3,000	220,980		Nov 25 04:29 PM
MARK A GOLDSMITH	Director	Nov 25 '25	Proposed Sale	73.66	60,000	4,419,600		Nov 25 04:28 PM
JACK LEE ANDERS	Officer	Nov 25 '25	Proposed Sale	73.66	5,418	399,090		Nov 25 04:25 PM
GOLDSMITH MARK A	See Remarks	Nov 18 '25	Option Exercise	4.09	20,000	81,800	267,863	Nov 20 04:23 PM
GOLDSMITH MARK A	See Remarks	Nov 18 '25	Sale	70.38	20,000	1,407,586	247,863	Nov 20 04:23 PM
Cislini Jeff	General Counsel	Nov 18 '25	Option Exercise	42.45	13,388	568,321	63,813	Nov 20 04:23 PM
Cislini Jeff	General Counsel	Nov 18 '25	Sale	70.14	13,388	939,008	50,425	Nov 20 04:23 PM
MARK A GOLDSMITH	Director	Nov 18 '25	Proposed Sale	69.14	20,000	1,382,800		Nov 18 04:23 PM
JEFFREY TODD CISLINI	Officer	Nov 18 '25	Proposed Sale	69.14	13,388	925,646		Nov 18 04:23 PM
GOLDSMITH MARK A	See Remarks	Nov 12 '25	Option Exercise	4.09	20,000	81,800	267,863	Nov 14 08:45 PM
GOLDSMITH MARK A	See Remarks	Nov 12 '25	Sale	65.07	20,000	1,301,410	247,863	Nov 14 08:45 PM
Anders Jack	Chief Financial Officer	Nov 11 '25	Option Exercise	17.00	10,000	170,000	120,994	Nov 13 04:20 PM
Anders Jack	Chief Financial Officer	Nov 11 '25	Sale	64.00	10,000	640,000	110,994	Nov 13 04:20 PM
GOLDSMITH MARK A	See Remarks	Nov 07 '25	Option Exercise	1.47	30,000	44,057	377,863	Nov 12 08:12 PM
GOLDSMITH MARK A	See Remarks	Nov 07 '25	Sale	60.31	30,000	1,809,306	347,863	Nov 12 08:12 PM
MARK A GOLDSMITH	Director	Nov 12 '25	Proposed Sale	64.08	20,000	1,281,600		Nov 12 04:40 PM
JACK LEE ANDERS	Officer	Nov 11 '25	Proposed Sale	62.73	10,000	627,300		Nov 12 07:04 AM
MARK A GOLDSMITH	Director	Nov 07 '25	Proposed Sale	61.38	30,000	1,841,400		Nov 07 04:38 PM
MARK A GOLDSMITH	Director	Oct 17 '25	Proposed Sale	49.68	10,000	496,800		Oct 17 04:18 PM
JEFFREY TODD CISLINI	Officer	Oct 17 '25	Proposed Sale	49.68	12,000	596,160		Oct 17 04:17 PM
MARK A GOLDSMITH	Director	Oct 16 '25	Proposed Sale	49.56	10,000	495,600		Oct 16 04:21 PM
Kelsey Stephen Michael	See Remarks	Oct 13 '25	Option Exercise	4.73	25,000	118,250	309,047	Oct 15 05:09 PM
Kelsey Stephen Michael	See Remarks	Oct 13 '25	Sale	48.54	25,000	1,213,540	284,047	Oct 15 05:09 PM
Cislini Jeff	General Counsel	Sep 24 '25	Sale	44.26	1,799	79,624	50,425	Sep 26 04:13 PM
JEFFREY TODD CISLINI	Officer	Sep 24 '25	Proposed Sale	44.21	1,799	79,525		Sep 24 04:21 PM
Wei Lin	Chief Medical Officer	Sep 16 '25	Sale	45.82	2,160	98,982	88,339	Sep 18 04:39 PM
Kelsey Stephen Michael	See Remarks	Sep 16 '25	Sale	45.82	5,367	245,942	284,047	Sep 18 04:38 PM
GOLDSMITH MARK A	See Remarks	Sep 16 '25	Sale	45.82	13,411	614,558	452,309	Sep 18 04:37 PM
Horn Margaret A	Chief Operating Officer	Sep 16 '25	Sale	45.82	4,775	218,814	145,900	Sep 18 04:36 PM
Cislini Jeff	General Counsel	Sep 16 '25	Sale	45.82	1,869	85,647	52,224	Sep 18 04:35 PM
Anders Jack	Chief Financial Officer	Sep 16 '25	Sale	45.82	2,320	106,314	110,994	Sep 18 04:34 PM
Wei Lin	Officer	Sep 15 '25	Proposed Sale	46.55	2,131	99,198		Sep 15 09:32 PM
Kelsey Stephen Michael	Officer	Sep 15 '25	Proposed Sale	46.55	5,296	246,529		Sep 15 09:28 PM
Horn Margaret A	Officer	Sep 15 '25	Proposed Sale	46.55	4,712	219,344		Sep 15 09:24 PM
GOLDSMITH MARK A	Officer	Sep 15 '25	Proposed Sale	46.55	13,236	616,136		Sep 15 09:20 PM
Cislini Jeff	Officer	Sep 15 '25	Proposed Sale	46.55	1,842	85,745		Sep 15 09:18 PM
Anders Jack	Officer	Sep 15 '25	Proposed Sale	46.55	2,128	99,058		Sep 15 09:14 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '25	Option Exercise	4.73	100,000	473,000	389,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 15 '25	Option Exercise	4.73	25,000	118,250	314,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 11 '25	Sale	44.08	100,000	4,408,482	289,414	Sep 15 08:51 PM
Kelsey Stephen Michael	See Remarks	Sep 15 '25	Sale	45.97	25,000	1,149,272	289,414	Sep 15 08:51 PM
STEPHEN M. KELSEY	Officer	Sep 11 '25	Proposed Sale	40.45	150,000	6,067,500		Sep 11 04:30 PM
Anders Jack	Chief Financial Officer	Sep 03 '25	Option Exercise	9.53	5,238	49,917	118,552	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 02 '25	Option Exercise	3.52	4,762	16,756	118,076	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 03 '25	Sale	40.17	5,238	210,432	113,314	Sep 04 07:05 PM
Anders Jack	Chief Financial Officer	Sep 02 '25	Sale	40.02	4,762	190,560	113,314	Sep 04 07:05 PM
JACK LEE ANDERS	Officer	Sep 02 '25	Proposed Sale	37.97	10,000	379,700		Sep 02 04:41 PM
GOLDSMITH MARK A	See Remarks	Jun 30 '25	Option Exercise	0.54	37,000	19,980	465,720	Jul 02 04:11 PM
Cislini Jeff	General Counsel	Jun 20 '25	Sale	39.61	1,912	75,736	54,093	Jun 23 04:07 PM
JEFFREY TODD CISLINI	Officer	Jun 20 '25	Proposed Sale	39.93	1,912	76,346		Jun 20 04:23 PM
Horn Margaret A	Chief Operating Officer	Jun 16 '25	Sale	39.83	3,510	139,803	150,675	Jun 18 04:06 PM
GOLDSMITH MARK A	See Remarks	Jun 16 '25	Sale	39.83	13,496	537,546	428,720	Jun 18 04:06 PM
Cislini Jeff	General Counsel	Jun 16 '25	Sale	39.83	1,878	74,801	56,005	Jun 18 04:06 PM
Anders Jack	Chief Financial Officer	Jun 16 '25	Sale	39.83	2,170	86,431	113,314	Jun 18 04:05 PM
Kelsey Stephen Michael	See Remarks	Jun 16 '25	Sale	39.83	4,289	170,831	289,414	Jun 18 04:05 PM
Wei Lin	Chief Medical Officer	Jun 16 '25	Sale	39.83	2,173	86,551	90,499	Jun 18 04:05 PM
Wei Lin	Officer	Jun 16 '25	Proposed Sale	40.79	2,131	86,923		Jun 13 05:25 PM
Kelsey Stephen Michael	Officer	Jun 16 '25	Proposed Sale	40.79	3,732	152,228		Jun 13 05:05 PM
Horn Margaret A	Officer	Jun 16 '25	Proposed Sale	40.79	3,320	135,423		Jun 13 05:03 PM
GOLDSMITH MARK A	Officer	Jun 16 '25	Proposed Sale	40.79	13,235	539,856		Jun 13 05:00 PM
Cislini Jeff	Officer	Jun 16 '25	Proposed Sale	40.79	1,842	75,135		Jun 13 04:58 PM
Anders Jack	Officer	Jun 16 '25	Proposed Sale	40.79	2,127	86,760		Jun 13 04:55 PM
Cislini Jeff	General Counsel	Mar 20 '25	Sale	38.71	2,041	79,008	57,723	Mar 24 04:55 PM
JEFFREY TODD CISLINI	Officer	Mar 20 '25	Proposed Sale	38.75	2,041	79,089		Mar 20 04:32 PM
Cislini Jeff	General Counsel	Mar 17 '25	Sale	39.04	1,458	56,921	59,764	Mar 19 05:43 PM
GOLDSMITH MARK A	See Remarks	Mar 17 '25	Sale	39.04	11,738	458,255	441,564	Mar 19 05:43 PM
Anders Jack	Chief Financial Officer	Mar 17 '25	Sale	39.04	1,864	72,771	115,006	Mar 19 05:42 PM
Horn Margaret A	Chief Operating Officer	Mar 17 '25	Sale	39.04	3,058	119,385	153,533	Mar 19 05:41 PM
Kelsey Stephen Michael	See Remarks	Mar 17 '25	Sale	39.04	3,294	128,599	293,051	Mar 19 05:40 PM
Anders Jack	Officer	Mar 17 '25	Proposed Sale	38.89	2,108	81,980		Mar 14 05:42 PM
Cislini Jeff	Officer	Mar 17 '25	Proposed Sale	38.89	1,650	64,168		Mar 14 05:14 PM
Kelsey Stephen Michael	Officer	Mar 17 '25	Proposed Sale	38.89	3,611	140,432		Mar 14 04:47 PM
Horn Margaret A	Officer	Mar 17 '25	Proposed Sale	38.89	3,406	132,459		Mar 14 04:18 PM
GOLDSMITH MARK A	Officer	Mar 17 '25	Proposed Sale	38.89	11,890	462,402		Mar 14 04:09 PM

RVMD

Revolution Medicines Inc

TNGX

Tango Therapeutics Inc

Upgrade your FINVIZ experience